Labiotech

The rise of cancer vaccines: A new era in immunotherapy
Source: Labiotech Published on 2024-12-02
Trump’s healthcare picks: Who they are and what they mean for the biopharma industry
Source: Labiotech Published on 2024-11-29
Can biotech beat mosquito-borne diseases?
Source: Labiotech Published on 2024-11-29
Six antisense oligonucleotide companies shaping the future of genetic medicine
Source: Labiotech Published on 2024-11-28
Charcot–Marie–Tooth disease: what’s going on in the clinical field?
Source: Labiotech Published on 2024-11-27
Seven miRNA-focused companies pioneering new therapies in 2024
Source: Labiotech Published on 2024-11-26
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Source: Labiotech Published on 2024-11-26
Evotec on the brink of acquisition: At what cost for the biotech industry?
Source: Labiotech Published on 2024-11-25
Can AlphaFold3’s open-source platform revolutionize the way we discover drugs?
Source: Labiotech Published on 2024-11-22
Could antigen modulation address autoimmune diseases?
Source: Labiotech Published on 2024-11-22
Huntington’s disease: a therapeutic field on a bumpy ride
Source: Labiotech Published on 2024-11-21
Eight areas where gene therapy shines
Source: Labiotech Published on 2024-11-21
Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024
Source: Labiotech Published on 2024-11-20
Six bispecific antibody companies you should know about
Source: Labiotech Published on 2024-11-19
What is Abcam’s founder, Jonathan Milner, up to?
Source: Labiotech Published on 2024-11-18